Fri Aug 4 16:55:15 2006
Robust hepatitis C virus infection in vitro
Zhong J, Gastaminza P, Cheng GF, et al.
PNAS 102 (26): 9294-9299 JUN 28 2005
and citing papers
stopwords, and 2-character and smaller words are excluded, Word count: 611, All words count: 910
Grand TLCS: 121, Grand TGCS: 212| View: Overview | Sorted by GCS. |
Page 1 of 2: [ 1 2 ]
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 1 | HEPATITIS | 58 | 120 | 210
|
| 2 | VIRUS | 54 | 115 | 186
|
| 3 | ROBUST | 2 | 73 | 73
|
| 4 | VITRO | 3 | 73 | 73
|
| 5 | INFECTION | 4 | 72 | 72
|
| 6 | ANTIVIRAL | 6 | 7 | 42
|
| 7 | PROTEIN | 4 | 7 | 42
|
| 8 | ADAPTOR | 1 | 7 | 41
|
| 9 | CARDIF | 1 | 7 | 41
|
| 10 | PATHWAY | 1 | 7 | 41
|
| 11 | RIG-I | 1 | 7 | 41
|
| 12 | TARGETED | 1 | 7 | 41
|
| 13 | HOST | 3 | 6 | 22
|
| 14 | REPLICATION | 10 | 10 | 22
|
| 15 | DEFENCE | 1 | 3 | 19
|
| 16 | EVASION | 1 | 3 | 19
|
| 17 | INTRACELLULAR | 2 | 3 | 19
|
| 18 | INTERFERON | 4 | 4 | 16
|
| 19 | MECHANISM | 2 | 3 | 16
|
| 20 | RIBAVIRIN | 2 | 4 | 16
|
| 21 | ACTION | 1 | 3 | 15
|
| 22 | FUNCTION | 2 | 8 | 15
|
| 23 | GENOME | 2 | 8 | 15
|
| 24 | TREATMENT | 1 | 3 | 15
|
| 25 | UNRAVELLING | 1 | 8 | 15
|
| 26 | INFECTIOUS | 8 | 7 | 9
|
| 27 | INTERACTIONS | 2 | 3 | 9
|
| 28 | UNSCRAMBLING | 1 | 3 | 9
|
| 29 | VIRUS-HOST | 1 | 3 | 9
|
| 30 | CELL | 9 | 7 | 8
|
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 31 | CULTURE | 5 | 5 | 6
|
| 32 | PROSPECTS | 1 | 1 | 6
|
| 33 | VACCINE | 1 | 1 | 6
|
| 34 | ENTRY | 6 | 5 | 5
|
| 35 | GLYCOPROTEINS | 2 | 4 | 5
|
| 36 | PRODUCTION | 4 | 4 | 5
|
| 37 | SYSTEM | 3 | 5 | 5
|
| 38 | ACTIVATION | 3 | 4 | 4
|
| 39 | ANALYSIS | 3 | 2 | 4
|
| 40 | CELLS | 7 | 4 | 4
|
| 41 | COMPLEX | 1 | 2 | 4
|
| 42 | HEPATOMA | 3 | 4 | 4
|
| 43 | HUMAN | 6 | 4 | 4
|
| 44 | LOW-PH-TRIGGERED | 1 | 4 | 4
|
| 45 | QUANTITATIVE | 2 | 2 | 4
|
| 46 | TEMPERATURE-DEPENDENT | 1 | 4 | 4
|
| 47 | TIME-AND | 1 | 4 | 4
|
| 48 | DIFFERENCE | 1 | 3 | 3
|
| 49 | EFFICIENT | 1 | 3 | 3
|
| 50 | FUSION | 2 | 3 | 3
|
| 51 | HCV | 6 | 2 | 3
|
| 52 | INHIBITS | 3 | 2 | 3
|
| 53 | LIPOSOMES | 1 | 3 | 3
|
| 54 | LOW | 1 | 3 | 3
|
| 55 | MEDIATE | 2 | 3 | 3
|
| 56 | MEMBRANE | 1 | 3 | 3
|
| 57 | PH-DEPENDENT | 1 | 3 | 3
|
| 58 | APOPTOSIS | 1 | 1 | 2
|
| 59 | ASSEMBLY | 1 | 1 | 2
|
| 60 | CDNA-TRANSFECTED | 1 | 2 | 2
|
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 61 | CIRCLE | 1 | 1 | 2
|
| 62 | CONCOMITANT | 1 | 1 | 2
|
| 63 | COUNTERS | 1 | 0 | 2
|
| 64 | CULTURE-GROWN | 1 | 2 | 2
|
| 65 | FULL | 1 | 1 | 2
|
| 66 | FUNCTIONAL | 2 | 1 | 2
|
| 67 | GENOTYPE | 3 | 1 | 2
|
| 68 | IMMUNITY | 1 | 0 | 2
|
| 69 | INCORPORATION | 1 | 1 | 2
|
| 70 | INNATE | 2 | 0 | 2
|
| 71 | INTERFERING | 1 | 0 | 2
|
| 72 | INTERFERONS | 1 | 0 | 2
|
| 73 | INTRACELLULARLY | 1 | 1 | 2
|
| 74 | OCCURS | 1 | 1 | 2
|
| 75 | PSEUDOPARTICLES | 1 | 1 | 2
|
| 76 | RECOMBINANT | 1 | 1 | 2
|
| 77 | RECULTURED | 1 | 2 | 2
|
| 78 | REQUIRES | 2 | 1 | 2
|
| 79 | RNA | 8 | 0 | 2
|
| 80 | STABLY | 1 | 2 | 2
|
| 81 | TISSUE | 2 | 1 | 2
|
| 82 | VIRAL | 5 | 1 | 2
|
| 83 | VIVO | 2 | 2 | 2
|
| 84 | ADVANCES | 1 | 0 | 1
|
| 85 | ANTI-HEPATITIS | 1 | 1 | 1
|
| 86 | BIOLOGICAL | 2 | 0 | 1
|
| 87 | CELL-BASED | 1 | 0 | 1
|
| 88 | CLINICAL | 1 | 0 | 1
|
| 89 | CONFLUENCE-BASED | 1 | 0 | 1
|
| 90 | CONTROL | 1 | 1 | 1
|
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 91 | CULTURED | 1 | 1 | 1
|
| 92 | DETECTION | 1 | 1 | 1
|
| 93 | DEVELOPMENT | 2 | 0 | 1
|
| 94 | DRUG | 1 | 0 | 1
|
| 95 | EFFECT | 3 | 0 | 1
|
| 96 | EFFECTS | 2 | 1 | 1
|
| 97 | EFFICIENTLY | 1 | 1 | 1
|
| 98 | EXPRESSION | 3 | 0 | 1
|
| 99 | FACE | 1 | 0 | 1
|
| 100 | FEATURES | 1 | 1 | 1
|
| 101 | FUTURE | 1 | 0 | 1
|
| 102 | GROWTH | 1 | 0 | 1
|
| 103 | HIGHLY | 1 | 0 | 1
|
| 104 | HUTCHINSON | 1 | 1 | 1
|
| 105 | IFN-BETA | 1 | 1 | 1
|
| 106 | INHIBITION | 2 | 0 | 1
|
| 107 | INHIBITOR | 4 | 0 | 1
|
| 108 | INTERFERON-SENSITIVE | 1 | 0 | 1
|
| 109 | LIPOPROTEIN | 2 | 1 | 1
|
| 110 | LOCALIZATION | 1 | 1 | 1
|
| 111 | LOW-DENSITY | 1 | 1 | 1
|
| 112 | MODELS | 1 | 0 | 1
|
| 113 | MOLECULAR | 2 | 1 | 1
|
| 114 | NOVEL | 2 | 0 | 1
|
| 115 | OXIDIZED | 1 | 1 | 1
|
| 116 | PESTIVIRUS | 1 | 0 | 1
|
| 117 | POLYMERASE | 2 | 0 | 1
|
| 118 | PRACTICE | 1 | 0 | 1
|
| 119 | PROMOTER | 1 | 1 | 1
|
| 120 | PROTEINS | 3 | 1 | 1
|
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 121 | RECENT | 1 | 0 | 1
|
| 122 | REPLICATES | 1 | 1 | 1
|
| 123 | REPLICON | 6 | 1 | 1
|
| 124 | REVEALED | 1 | 1 | 1
|
| 125 | RNA-DEPENDENT | 1 | 0 | 1
|
| 126 | SALIENT | 1 | 1 | 1
|
| 127 | SELECTIVE | 1 | 0 | 1
|
| 128 | SENSITIVE | 1 | 1 | 1
|
| 129 | STIMULATOR | 1 | 1 | 1
|
| 130 | STRAIN | 2 | 1 | 1
|
| 131 | STRUCTURAL | 1 | 1 | 1
|
| 132 | SUBCELLULAR | 1 | 1 | 1
|
| 133 | SUSTAINED | 1 | 0 | 1
|
| 134 | TARGETS | 2 | 0 | 1
|
| 135 | THERAPEUTIC | 3 | 1 | 1
|
| 136 | TRANSLATION | 1 | 0 | 1
|
| 137 | VIROLOGIC | 1 | 0 | 1
|
| 138 | ACHILLES | 1 | 0 | 0
|
| 139 | ACTIVE | 1 | 0 | 0
|
| 140 | ACTIVITIES | 1 | 0 | 0
|
| 141 | ACTIVITY | 2 | 0 | 0
|
| 142 | ADAPTIVE | 1 | 0 | 0
|
| 143 | ALPHA | 1 | 0 | 0
|
| 144 | ALPHA-GLUCOSIDASE | 1 | 0 | 0
|
| 145 | ANALYSES | 1 | 0 | 0
|
| 146 | ANTI-HCV | 1 | 0 | 0
|
| 147 | ANTIBODIES | 1 | 0 | 0
|
| 148 | ANTIBODY | 1 | 0 | 0
|
| 149 | APOB-CONTAINING | 1 | 0 | 0
|
| 150 | APOLIPOPROTEIN | 1 | 0 | 0
|
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 151 | APPLIED | 1 | 0 | 0
|
| 152 | APPROACH | 1 | 0 | 0
|
| 153 | ASSAY | 2 | 0 | 0
|
| 154 | BASIC | 1 | 0 | 0
|
| 155 | BILIARY | 1 | 0 | 0
|
| 156 | BINDING | 2 | 0 | 0
|
| 157 | BREAKTHROUGH | 1 | 0 | 0
|
| 158 | BROADLY | 1 | 0 | 0
|
| 159 | CAPTURING | 1 | 0 | 0
|
| 160 | CARCINOMA | 1 | 0 | 0
|
| 161 | CELL-CELL | 1 | 0 | 0
|
| 162 | CHARACTERIZATION | 4 | 0 | 0
|
| 163 | CHIMERAS | 1 | 0 | 0
|
| 164 | CLA | 1 | 0 | 0
|
| 165 | CLATHRIN-MEDIATED | 1 | 0 | 0
|
| 166 | CLEAVAGE | 1 | 0 | 0
|
| 167 | COMBINATION | 1 | 0 | 0
|
| 168 | CONSTRUCTION | 1 | 0 | 0
|
| 169 | CORE-RNA | 1 | 0 | 0
|
| 170 | CULTURES | 1 | 0 | 0
|
| 171 | CYCLOSPORIN | 1 | 0 | 0
|
| 172 | CYCLOSPORINE | 1 | 0 | 0
|
| 173 | CYTOSKELETON | 1 | 0 | 0
|
| 174 | DC-SIGN | 1 | 0 | 0
|
| 175 | DC-SIGNR | 1 | 0 | 0
|
| 176 | DEBIO | 1 | 0 | 0
|
| 177 | DEFINED | 1 | 0 | 0
|
| 178 | DELETION | 1 | 0 | 0
|
| 179 | DENSITY | 1 | 0 | 0
|
| 180 | DEPENDS | 1 | 0 | 0
|
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 181 | DIFFERENT | 2 | 0 | 0
|
| 182 | DIHYDROXY-4-CARBOXYPYRIMIDINES | 1 | 0 | 0
|
| 183 | DIMERIZATION | 1 | 0 | 0
|
| 184 | DIRECT | 1 | 0 | 0
|
| 185 | DISCOVERY | 1 | 0 | 0
|
| 186 | DISORDERS | 1 | 0 | 0
|
| 187 | DISPENSABLE | 1 | 0 | 0
|
| 188 | DISTINCT | 2 | 0 | 0
|
| 189 | DIVERSE | 1 | 0 | 0
|
| 190 | DOMAINS | 1 | 0 | 0
|
| 191 | DSRNA-INDUCED | 1 | 0 | 0
|
| 192 | EARLY | 1 | 0 | 0
|
| 193 | EMPIRICISM | 1 | 0 | 0
|
| 194 | ENDOCYTOSIS | 1 | 0 | 0
|
| 195 | ENDOTHELIUM | 1 | 0 | 0
|
| 196 | ENGAGEMENT | 1 | 0 | 0
|
| 197 | ENHANCES | 1 | 0 | 0
|
| 198 | ENVELOPE | 1 | 0 | 0
|
| 199 | EPITOPE | 1 | 0 | 0
|
| 200 | ERADICATION | 1 | 0 | 0
|
Page 1 of 2: [ 1 2 ]